Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestin presented as a 13.5 mg intrauterine system for intrauterine use. It provides contraception and can be used to manage heavy menstrual bleeding in women of reproductive age. The device releases levonorgestrel locally over several years, offering a long‑acting reversible contraceptive option.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levonorgestrel delivered via the Jaydess intrauterine system acts on the reproductive hormonal pathway to provide long‑acting contraception and control of menstrual bleeding.

Contraception: provides highly effective, reversible birth control for up to three years, with a failure rate of less than 1 %. Heavy menstrual bleeding: reduces menstrual blood loss by up to 80 %, improving anemia and quality of life. Endometrial protection: maintains a thin endometrial lining, decreasing the risk of hyperplasia during prolonged hormonal exposure.

Levonorgestrel delivered via the Jaydess intrauterine system may be associated with a range of adverse reactions.

Common Side Effects: - Irregular bleeding: spotting or breakthrough bleeding, especially during the first months. - Amenorrhea: absence of menstrual periods after initial adjustment. - Pelvic pain: mild to moderate discomfort or cramping. - Headache: tension‑type or migraine‑like headaches. - Breast tenderness: mild swelling or sensitivity.

Serious or Rare Side Effects: - Uterine perforation: risk during insertion, may require surgical management. - Expulsion: device may be partially or completely expelled, needing re‑insertion. - Infection: pelvic inflammatory disease or endometritis following placement. - Hormone‑related thrombosis: rare cases of venous thromboembolism. - Allergic reaction: severe hypersensitivity with rash, swelling, or anaphylaxis.

Before using Jaydess, clinicians should consider several precautionary measures to ensure patient safety. - Patient selection: confirm that the woman is not pregnant and has no contraindications to progestin‑only contraception. - Uterine assessment: perform ultrasound or hysteroscopy to rule out fibroids, congenital anomalies, or infection. - Timing of insertion: insert within 5 days of menstrual onset or after confirmed negative pregnancy test. - Follow‑up: schedule a check‑up 4–6 weeks after placement to verify correct positioning. - Contraindications: avoid in women with active pelvic infection, unexplained vaginal bleeding, or known hypersensitivity to levonorgestrel. - Store at ambient temperature: keep the device in its original packaging, protect from moisture and direct sunlight, and store below 25 °C.

Levonorgestrel released from Jaydess can interact with other medicines that affect hormonal pathways or hepatic metabolism.

Major Interactions (Avoid): - Enzyme inducers: strong CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine) may reduce levonorgestrel efficacy. - Antifungal agents: concomitant use of itraconazole can increase systemic levonorgestrel levels, potentially raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Antiretrovirals: protease inhibitors may alter hormone levels; monitor for breakthrough bleeding. - Anticonvulsants: moderate enzyme inducers (e.g., oxcarbazepine) may modestly decrease effectiveness. - Herbal supplements: St. John’s wort may reduce contraceptive reliability; advise caution.